Intraoperative neuromonitoring company Assure Holdings saw its second quarter 2022 managed case volume jump by about 36 percent year-over-year.
Assure's case volume for the full year is expected to grow by more than 40 percent, the company said Aug. 15. It expects a positive adjusted EBITDA in the second half of the year.
The company saw a second quarter net loss of $4.7 million, and a net loss per diluted share of $0.37, both steeper losses than over the same period in 2021.
"Given recent economic and capital markets uncertainty, Assure began a strategic cost-reduction effort that we expect will yield over $4.5 million of annualized savings," Assure's CEO and executive chair John Farlinger said in a company call. "As a result, we expect to become cash flow positive on an adjusted operating basis in the second half of 2022."